

Promoter variants in the *MSMB* gene associated with prostate cancer regulate *MSMB/NCOA4* fusion transcripts

Hong Lou · Hongchuan Li · Meredith Yeager · Kate Im · Bert Gold · Thomas D. Schneider · Joseph F. Fraumeni Jr. · Stephen J. Chanock · Stephen K. Anderson · Michael Dean

Received: 5 April 2012 / Accepted: 11 May 2012 / Published online: 4 June 2012
© Springer-Verlag (outside the USA) 2012

Abstract Beta-microseminoprotein (MSP)/*MSMB* is an immunoglobulin superfamily protein synthesized by prostate epithelial cells and secreted into seminal plasma. Variants in the promoter of the *MSMB* gene have been associated with the risk of prostate cancer (PCa) in several independent genome-wide association studies. Both *MSMB* and an adjacent gene, *NCOA4*, are subjected to transcriptional control via androgen response elements. The gene product of *NCOA4* interacts directly with the androgen receptor as a co-activator to enhance AR transcriptional activity. Here, we provide evidence for the expression of full-length *MSMB-NCOA4* fusion transcripts regulated by

the *MSMB* promoter. The predominant *MSMB-NCOA4* transcript arises by fusion of the 5'UTR and exons 1–2 of the *MSMB* pre-mRNA, with exons 2–10 of the *NCOA4* pre-mRNA, producing a stable fusion protein, comprising the essential domains of *NCOA4*. Analysis of the splice sites of this transcript shows an unusually strong splice acceptor at *NCOA4* exon 2 and the presence of *Alu* repeats flanking the exons potentially involved in the splicing event. Transfection experiments using deletion clones of the promoter coupled with luciferase reporter assays define a core *MSMB* promoter element located between –27 and –236 of the gene, and a negative regulatory element immediately upstream of the start codon. Computational network analysis reveals that the *MSMB* gene is functionally connected to *NCOA4* and the androgen receptor signaling pathway. The data provide an example of how

H. Lou and H. Li contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s00439-012-1182-2) contains supplementary material, which is available to authorized users.

H. Lou
Human Genetics Section, Basic Research Program,
SAIC-Frederick Inc., National Cancer Institute-Frederick,
Frederick, MD 21702, USA

H. Li · S. K. Anderson
Molecular Immunology Section, Basic Research Program,
SAIC-Frederick Inc., National Cancer Institute-Frederick,
Frederick, MD 21702, USA

M. Yeager
Core Genotyping Facility, Advanced Technology Program,
SAIC-Frederick, Inc., National Cancer Institute-Frederick,
Frederick, MD 21702, USA

K. Im · B. Gold · S. K. Anderson (✉) · M. Dean (✉)
Cancer and Inflammation Program, Laboratory of Experimental
Immunology, Center for Cancer Research, National Cancer
Institute-Frederick, Frederick, MD 21702, USA
e-mail: andersonst@mail.nih.gov

M. Dean
e-mail: deanm@mail.nih.gov

T. D. Schneider
Gene Regulation and Chromosome Biology Laboratory,
Molecular Information Theory Group, Frederick,
MD 21702, USA

J. F. Fraumeni Jr. · S. J. Chanock
Division of Cancer Epidemiology and Genetics,
Center for Cancer Research, National Cancer Institute, NIH,
Bethesda, MD 20892, USA

GWAS-associated variants may have multiple genetic and epigenetic effects.

Abbreviations

ARE	Androgen response element
AR	Androgen receptor
GWAS	Genome-wide association studies
PCa	Prostate cancer

Introduction

Human prostate cancer (PCa) is the most common cancer affecting males in developed countries. Unlike many cancers, it is often indolent, multifocal, and genetic studies have failed to find a consistent high penetrance locus in its causation. PCa is a complex disease that involves interaction between genetic susceptibility and environmental factors, environment and socioeconomic status (Crawford 2003). MSP (beta-microseminoprotein), encoded by the *MSMB* gene, is secreted at high levels by the prostate, and variation in MSP levels can be easily detected in both the serum and semen via a validated immunoassay (Valtonen-Andre et al. 2008). MSP has potential utility as a diagnostic tool in detecting PCa, with several aspects of its molecular biology suggesting that it might be more specific for PCa than prostate-specific antigen (PSA) (Bjartell et al. 2007; Reeves et al. 2006). Nuclear receptor coactivator 4 (*NCOA4*, also known as 70 kDa androgen receptor coactivator or ARA70) is a ligand-dependent AR-associated protein that enhances the transcriptional activity of androgen receptor (AR) in human PCa cells in the presence of dihydrotestosterone or testosterone (Yeh and Chang 1996). As a potential facilitator of PCa progression, ARA70-induced AR transactivation may result in decreased apoptosis and increased cell proliferation in PCa cells via a PSA-mediated mechanism (Niu et al. 2008). In addition, overexpression of an alternatively spliced 35 kDa ARA70 variant, termed ARA70-beta, promoted cellular invasion in an AR-independent manner (Peng et al. 2008). ARA70 was first identified as a gene fused to an oncogene and subsequently as a co-activator for AR (Peng et al. 2008).

The *MSMB* promoter variant rs10993994 was identified in two independent genome-wide association studies (GWAS) to be significantly associated with the risk of PCa (Eeles et al. 2008; Thomas et al. 2008). Now that this region has been extensively re-sequenced, additional variants close to rs10993994 have been investigated. It has been shown that a variant located in the neighboring gene, *NCOA4*, may play a role in PCa (Chang et al. 2009), and may involve alleles of rs10993994 that differentially influence the expression of *MSMB* and *NCOA4* genes in

prostate tissue (Chang et al. 2009; Lou et al. 2009; Nacu et al. 2011; Pomerantz et al. 2010).

Among the genetic alterations that characterize many cancers is gene fusion, which often results in the production of a fusion protein that may have a new or altered function (Rabbitts 1994; Rowley 2001). Interestingly, about 80 % of all known gene fusions have been associated with bone and soft tissue sarcomas, leukemias, and lymphomas, which account for only 10 % of all human cancers (Mitelman et al. 2004). In contrast, common epithelial cancers, which account for 80 % of cancer-related deaths, have been associated with only 10 % of known recurrent gene fusions (Kumar et al. 2009; Mitelman et al. 2005). However, the recent discovery of a recurrent gene fusion, *TMPRSS2-ERG*, in a majority of prostate cancers (Tomlins et al. 2007) and *EML4-ALK* in non-small-cell lung cancer (NSCLC) (Soda et al. 2007), has provided impetus for a search for gene fusions in epithelial cancers (Choi et al. 2008; Koivunen et al. 2008; Perner et al. 2008; Rikova et al. 2007; Tomlins et al. 2005).

Intergenic trans-splicing, the joining of exons from distinct genes into one mature mRNA, has been shown to occur in mammalian cells and model organisms (Horiuchi and Aigaki 2006) and high-throughput sequencing reveals that trans-splicing and cis-splicing events are widespread in human cells (Al-Balool et al. 2011). Cis-splicing is a mechanism to generate hybrid proteins in adjacent genes, but its role in cancer is unclear. There is, however, precedent for investigating trans-splicing in cancer. Li et al. (2008) described intra-chromosomal trans-splicing of *JAZF1* and *JJAZF1* in normal endometrial stromal cells that mimics the aberrant hybrid transcript generated by the t(7;17)(p15;q21) translocation found in about 50 % of endometrial sarcomas, and speculated that the trans-splice product is pro-neoplastic. Similarly, *MDS1/EVI1* fusion transcripts were found in normal cells that mimic cancer-associated gene fusion products (Fears et al. 1996). In fact, intergenic splicing of *MDS1* and *EVI1* occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family (Fears et al. 1996). More recently, *SLC45A3/ELK4* trans-splicing was identified in benign prostate lesions (Rickman et al. 2009). These findings form the basis for an emerging concept that alternative splicing events may generate fusion protein expression that becomes a pivotal event in multi-step carcinogenesis.

The work described herein was stimulated by a series of observations: (1) *MSMB* and *NCOA4* are located less than 10 kb apart; (2) computational network analysis revealed that the *MSMB* gene is functionally connected with the *NCOA4* gene via the AR signaling pathway; (3) three reported expressed sequence tags (EST), DB215804, DB233878 and DB240089, indicate that *MSMB* and *NCOA4* form a complex locus in which mRNA transcripts

utilize exons from both genes (Thierry and Thierry 2006), and (4) *MSMB-NCOA4* fusion transcripts were identified in a recent study of read-through gene fusions in PCa (Nacu et al. 2011). The high relevance of these two genes to prostate tissue suggests a potential functional role for this fusion transcript in the development of PCa.

Results

Identification of *MSMB-NCOA4* fusion transcripts

MSMB and *NCOA4* are separated by ~3 kb on human chromosome 10q11 and three EST clones containing *MSMB* and *NCOA4* exons have been reported (Fig. 1a). To investigate transcription from that region, we designed primers corresponding to several different positions in known *MSMB* and *NCOA4* exons (Table S1). These were intended to identify fusion transcripts and determine their transcription start sites. A 2,027 bp *MSMB-NCOA4* fusion transcript was amplified using primers from the 5'UTR of *MSMB* exon 1 (RT-*MSMB-NCOA4* F1) and the 3'UTR of *NCOA4* exon 10 (RT-*MSMB-NCOA4* Rev1) (Fig. 1; S1). The *MSMB-NCOA4* fusion transcript, containing the full

sequence of *MSMB* exons 1–2 followed by complete sequences of *NCOA4* exons 2–10 (E2–E2) was consistently amplified from prostate tissues, normal trachea tissue, and five prostate cancer cell lines (see Fig. 1b).

Mapping the fusion gene transcription initiation site

To characterize the 5' start sites of the *MSMB-NCOA4* fusion transcripts, we performed 5' RACE experiments. Four novel *MSMB-NCOA4* transcripts were identified in this study from RNA of human prostate tissues, and normal trachea tissue (Fig. 1b). The first transcript, *MSMB-NCOA4* 1, represented a fusion of the complete exons 1–2 of *MSMB* with exons 2–10 of *NCOA4* (E2–E2) as described previously (see Figure S1). The second transcript, *MSMB-NCOA4* 2, contains exons 1–3 of *MSMB* fused with exons 2–10 of *NCOA4* (E3–E2). The third and fourth transcripts, *MSMB-NCOA4* 3 and 4, contain 5' sequence from the upstream *RPL23AP61* pseudogene fused to either exon 2 or exons 2–3 of *MSMB* followed by exons 2–10 of *NCOA4* at the 3' end (Fig. 1b; Figure S1). The *MSMB-NCOA4* 3 and 4 transcripts lack *MSMB* exon 1 sequence compared with *MSMB-NCOA4* 1 and 2. Sequencing of the first *MSMB-NCOA4* transcript revealed an open reading frame that




Fig. 1 Characterization of the *MSMB* gene and *MSMB-NCOA4* fusion transcripts. **a** UCSC genome browser view of *MSMB* and part of *NCOA4*. Three transcripts, DB215804, DB240089 and DB233878 span the *MSMB* and *NCOA4* genes. The region is shown from (51,217,500) to (51,261,000) on Chromosome 10q11. **b** Schematic organization of *MSMB* and *MSMB-NCOA4* fusion transcripts. The exons are indicated as *boxes* with corresponding exon numbers.

Sequences derived from *MSMB* are shown in *red*, from *NCOA4* are shown in *dark blue*, and from *RPL23AP61* is shown in *gray*. *Green boxes* represent untranslated regions. The structures of four fusion transcripts identified in this study by 5' RACE assay and sequencing, *MSMB-NCOA4* 1 to 4 are shown. Transcription orientations are indicated by *arrows* (color figure online)




Fig. 2 RT-PCR of *MSMB-NCOA4* fusion transcripts in human tissues and cancer cell lines. cDNA prepared from human prostate normal tissue (HPNT), human prostate tumor tissue (HPTT), human trachea normal tissue (HTNT) and 9 prostate cell lines was subjected to RT-PCR using two primer sets, the 5′*MSMB* exon1 primer (forward)/3′*NCOA4* exon10 (3′UTR, reverse) (2,027 bp), and the 5′*MSMB* exon 1 primer/3′*NCOA4* exons 5–6 (reverse) (643 bp)

creates a fusion protein. The other transcripts were only detected in tumor tissue by cloning and sequencing, without a visible band by RT-PCR (Fig. 2).

MSMB-NCOA4 fusion protein expression in vitro and in cell lines

Sequence analysis of *MSMB-NCOA4* 1 (E2-E2) revealed a 2,027 bp cDNA including 32 bp of the 5′UTR of *MSMB* and 27 bp of the 3′UTR of *NCOA4*, generating an ORF of 656 aa, putatively encoding an ~73 kDa protein from the fusion transcript. This structure of *MSMB-NCOA4* has the potential to encode a protein with two distinct domains,

MSMB at its amino (N) terminus and *NCOA4* at its carboxyl (C) terminus.

To determine if the *MSMB-NCOA4* fusion protein can be expressed, we performed in vitro transcription/translation of the *MSMB-NCOA4* cDNA. As shown in Fig. 3a, a specific signal was observed at 73 kDa. PC3 cells were then transiently transfected for 72 h with the pcDNA3.1⁺-*MSMB-NCOA4* vector carrying the full *MSMB-NCOA4* fusion transcript. Protein expression was verified by western blot analysis of cell lysates using a polyclonal anti-*MSMB* antibody affinity-purified on a peptide encompassing amino acids 21–144 of the *MSMB* N-terminus, and a monoclonal anti-*NCOA4* antibody on a peptide encompassing amino acids 505–615 of *NCOA4* C-terminus (Fig. 3b). The anti-*MSMB* antibody recognized the endogenous (15 kDa) and recombinant (18 kDa) *MSMB* proteins in *MSMB* transfectants containing a Myc-DDK-tag (Fig. 3b). The anti-*NCOA4* C terminus antibody did not react with lysates of *MSMB* transfectants, but showed a specific signal with *NCOA4* transfectants (Fig. 3b). The lysates of PC3 transfected with the *MSMB-NCOA4* expression vector showed a specific band at 73 kDa, when probed with either anti-*MSMB* or anti-*NCOA4* antibodies. To further confirm the identity of the *MSMB-NCOA4* fusion protein, we performed immunoprecipitation with either the anti-*MSMB* N-terminal or the anti-*NCOA4* C-terminal antibody. Western blotting of immunoprecipitated protein with either anti-*NCOA4* (Fig. 3c, left panel) or anti-*MSMB* (Fig. 3c, right panel) showed a specific signal around 73 kDa.

The expression of *MSMB-NCOA4* in transfected prostate cancer cell lines

To confirm expression of the fusion protein, we amplified the full-length *MSMB-NCOA4* 1 (E2-E2) transcript from




Fig. 3 Expression of *MSMB-NCOA4* fusion protein in the transfected PC3 cell line. **a** Expression of the *MSMB-NCOA4*-encoded protein in vitro using the TNT system. **b** Western blotting analysis of the fusion construct. PC3 cells transfected with the pcDNA3.1⁺ empty vector, the pcDNA3.1⁺-*MSMB-NCOA4* expression vector,

pcMV6-*NCOA4* and pcMV6-*PSP94* were analyzed by western blot using polyclonal anti-*MSMB* antibody (left panel) and monoclonal anti-*NCOA4* antibody (right panel). **c** Immunoprecipitation (IP) using anti-*MSMB* raised against the N-terminus of *MSMB* (left panel) or anti-*NCOA4* against the C-terminus of *NCOA4* (right panel)




Fig. 4 Transfection with expression vectors carrying the *MSMB-NCOA4* fusion transcript. **a** Transfection efficiency was shown by GFP-positive cells. The extent of EGFP expression in PC3 was determined following transfection with the pEGFPC1-*MSMB-NCOA4* plasmid using fluorescence microscopy. **b** RT-PCR amplification of the *MSMB-NCOA4* fusion gene using RT-*MSMB-NCOA4* F1 and RT-*MSMB-NCOA4* Rev1 primer pairs in PC3, DU145 and LNCaP cells transfected with pcDNA3.1⁺-*MSMB-NCOA4* and pcDNA3.1⁺ vector only. RT (+) is shown in the *top panel*, and RT

(−) is shown in the *bottom panel*. **c** Expression level of the *MSMB-NCOA4* fusion transcript in transfected PC3 cells by TaqMan real-time RT-PCR using primer and probe sets corresponding to different exons of *MSMB* and *NCOA4* genes (Table S2). Overexpression was confirmed using primer/probe sets containing *MSMB* exons 1–2 and *NCOA4* exons 6–7, but no overexpression was observed when primer/probe sets containing *MSMB* exons 2–3 and *NCOA4* exons 1–2 were used. Relative quantities of the fusion transcript were normalized by beta-actin, and calibrated to control sample (PC3 only)

normal prostate tissue and inserted it into the expression vectors, pcDNA3.1⁺ and pEGFPC1, respectively. These expression vectors and commercially available pCMV6-*NCOA4* and pCMV6-PSP94 vectors were transiently transfected into PC3, LNCaP and DU145 cells (Fig. 4a).

MSMB-NCOA4 mRNA was overexpressed in three cell lines transfected with an expression vector carrying *MSMB-NCOA4* fusion transcript, compared with the vector-only control (Fig. 4b). Of them, PC3 showed the highest expression level of *MSMB-NCOA4*. We developed two TaqMan real-time PCR primer and probe sets to target different regions of *MSMB* (*MSMB* I across exons 1–2 and *MSMB* II across exons 2–3 of *MSMB*) and *NCOA4* (*NCOA4* I across exons 1–2 and *NCOA4* II across exons 6–7 of *NCOA4*) (Table S1). The results show high expression of the fusion transcript in transfected PC3 cells using *MSMB* I and *NCOA4* II assays (Fig. 4c).

Co-regulation of the expression of *MSMB* and *MSMB-NCOA4* fusion transcripts in human tissue and cancer cell lines

To determine whether the expression of the fusion transcript is regulated by the *MSMB* promoter, we analyzed its expression in normal prostate tissue, prostate tumor tissue, trachea tissue, and prostate cancer cell lines using RT-PCR followed by agarose gel electrophoresis. A 2,027 bp RT-PCR product was identified in tissues from 5 of 9 prostate tumor cell lines, including PCa2b, NCI H660, PC3, LNCaP and RWPE1, using a forward RT-*MSMB-NCOA4* F1 primer located in the 5'UTR of *MSMB* and a reverse primer, RT-*MSMB-NCOA4* Rev1, located in the 3'UTR of *NCOA4* (Table S1; Fig. 2, top panel). Using another reverse primer, RT-*MSMB-NCOA4* Rev2, we detected a 643-bp RT-PCR product, with exactly the same tissue and

cell distribution as the products obtained using the RT-*MSMB-NCOA4* Rev1 primer (Fig. 2, middle panel). While all tissues expressed the *MSMB-NCOA4* fusion transcripts, normal prostate tissue showed the highest expression level.


To further survey for the presence of *MSMB-NCOA4* fusion transcripts in tissues and cell lines, we developed a TaqMan real-time RT-PCR assay using an absolute quantitation method (see “Materials and methods” for details). Using this assay, the *MSMB-NCOA4* fusion transcript was detected in 14 of 26 tumor cell lines and all eight human tissues (Table S2), and, again, was expressed at the highest level in normal human prostate tissue compared with other tissues and cells. We also examined levels of *MSMB*, *NCOA4* and *AR* mRNA expression in relation to the fusion transcripts (Table S2). Expression of the *MSMB-NCOA4* fusion transcript was positively correlated with *MSMB* expression in tissues and cancer cell lines in a statistically significant manner. The Pearson correlation for the value of *MSMB-NCOA4* transcript I and *MSMB* transcription is 0.70, yielding a two-tailed *P* value of $\sim 6.6 \times 10^{-6}$.

Functional analysis of *MSMB* promoter activity by deletion mapping

In silico promoter region prediction and gene analysis were performed using the EIDorado and Gene2Promoter online programs. The potential promoter region upstream of the *MSMB* gene was predicted by interspecies comparison. Multiple promoter elements are located immediately upstream of *MSMB* exon 1, and likely play a role in the regulation of *MSMB* expression (Fig. 5).

To determine the minimal sequences required for promoter function and identify cis-acting elements controlling *MSMB* promoter activity, a series of truncated luciferase

Fig. 5 Identification of promoter elements of the *MSMB* gene using EIDorado. Three potential promoter regions surrounding the *MSMB* gene are shown. Promoter element 1 is located adjacent to the *MSMB* 5'UTR region. The promoter elements 2 and 3 are located 17 kb upstream and 5.3 kb downstream of the *MSMB* transcription start site, respectively



constructs were generated by progressive deletions at the 5' end of a 752 bp fragment (−716/+36) comprising the putative promoter region, to produce nine constructs (Fig. 6a). Plasmids containing the *MSMB* gene fragments were transiently transfected into three prostate cancer cell lines and the promoter activity was measured as described in the “Materials and methods”.

As shown in Fig. 6a, luciferase activity was not diminished by deleting DNA up to position −236; rather, an increase in promoter activity was observed for this construct when compared with the original PGL3−716/+36 reporter in PC3 and DU145 cell lines. The highest promoter activity was observed in the construct PGL3−236/+36. Further deletions decreased promoter activity significantly. However, no promoter activity change was found in LNCaP cells (Fig. 6a).

The above data suggest that sequences contained between nucleotides (nt)−236 and +36 in PGL3−716/+36 construct bear the cis-acting elements required for maximal *MSMB* transcriptional activation, and this reporter vector as well as PGL3−373/+36 was used for the following 3' deletion analysis. It should be noted, however, that the regions from nt −373 to −284 might contain additional negative cis-regulatory elements, relevant in the context of prostate cancer PC3 and DU145 cells.

To further identify the 3' boundary of the core promoter, a series of plasmids were constructed sharing the same 5' boundaries at either position −373 or −236, and variable 3' ends from +36 to −83. The deletion constructs were transiently transfected in PC3, DU145 and LNCaP human prostate cancer cell lines, and luciferase activities were

measured. As shown in Fig. 6b, the deletion from +36 to +25 within the *MSMB* core promoter region resulted in a 5-fold increase in luciferase activity, and the deletion from +25 to −27 resulted in a 19-fold and 24-fold increase in PC3 and DU145 cells, respectively (Fig. 6b). In contrast to the results from the 5' deletion analysis, luciferase activity in LNCaP cells transfected with the 3' deletion constructs showed 3.5-fold to 7-fold increases with the +25 to −27 deletions. Further deletions (−58, −83) dramatically reduced promoter activity, indicating that the core promoter is contained within the −236 to −27 region. These results suggested that sequences contained in the 210 bp proximal to the transcription initiation site are necessary and sufficient for *MSMB* promoter activity, and inhibitory elements were identified in both distal and proximal areas of the *MSMB* promoter. These two regulatory elements in the distal and proximal regions of the *MSMB* promoter were thus confirmed (Fig. 7). The 210 bp core promoter had the highest transcription activity in all the prostate cancer cell lines we tested, indicating that this fragment is responsible for basal *MSMB* promoter activity. Because deletion of the immediate 5'UTR results in significantly enhanced transcription activity in the prostate cancer cell lines, we suggest that there are negative cis-acting elements in this region.

Computational analysis of splice sites participating in *MSMB*-NCOA4 fusion transcripts

To begin to explore the mechanism of generation of the hybrid *MSMB*-NCOA4 fusions, we characterized the splice




Fig. 6 Functional localization of the *MSMB* promoter. A schematic of the *MSMB* gene structure is shown above. Four *MSMB* exons are indicated by the numbered green rectangles. A schematic diagram of the 1,000 bp 5'-flanking region of *MSMB* exon 1 and 5' serial (a) or 3' serial (b) truncation constructs of the *MSMB* promoter and their corresponding luciferase activities in different cell types are shown. Serial deletions at the 5' and the 3' ends of the promoter fragment of *MSMB* are shown on the left. The promoter activities measured after transfection into PC3, DU145 and LNCaP cells are shown on the

right. The relative size and position of fragments cloned into the pGL3 vector are indicated by the lines below the schematic, and the numbers in parentheses on either side of each fragment indicate the distance in nucleotides upstream from the *MSMB* start codon of the 5' and 3' ends of each fragment. The luciferase activity of the pGL3 constructs is shown as fold-increase of corrected light units relative to an empty pGL3 vector control. Values represent the mean, and error bars indicate the SEM of at least three independent experiments (color figure online)

sites, flanking sequences and branch point surrounding the exons involved using information theory-based methods (Rogan et al. 1998). We identified that the *MSMB* exon 2 participating in the major trans-splice transcript contains a strong splice donor and the splice acceptor for exon 2 of *NCOA4* is extremely strong (Fig. 8). At 15.6 bits the acceptor of exon 2 of *NCOA4* is in the strongest ~4 % of acceptors in the genome. We also identified *Alu* sequences immediately downstream of *MSMB* exon 2 and upstream of *NCOA4* exon 2 that may contribute to splicing (Fig. 8, see “Discussion”).

In silico identification of potential cis regulatory elements of the *MSMB* promoter

The *MSMB* -236/-27 promoter fragment exhibited the highest transcriptional activity in the luciferase reporter assay. We therefore performed a computational analysis of the *MSMB* core promoter sequence to identify potential cis regulatory elements using the MatInspector and TFSEARCH programs. Analysis revealed putative binding sites for various transcription factors (Fig. 7b) and, of these, CREB, MYOD, STAT, OCT, PBXC, ETS, SP1,




Fig. 7 Schematic model of regulatory binding sites 5' to the *MSMB* and *NCOA4* genes. **a** Potential androgen response elements (AREs) upstream of *MSMB* and in between *MSMB* and *NCOA4* in the top 15 sequences examined. Scores were derived from a frequency matrix built based on (Denayer et al. 2010). The sequences for the potential AREs are GGGTCACAAAGTTCT, CACTCAATGTGTCT,

GGTTCAGGCAGTTCT, and AGAGAACCCTGTCT for ARE1, ARE2, ARE3, and ARE4, respectively. **b** A schematic of predicted transcription factor binding modules in the proximal *MSMB* promoter region. Predictions are organized into three groups, one core regulatory element group and two negative regulatory element groups




Fig. 8 A conceptual model for splicing of the *MSMB*/*NCOA4* transcripts. A reverse transcript of an Alu element may base pair with the two independent mRNA transcripts or within a single transcript to form a helix with a crossover as in a Holliday junction. The junction would be in the middle of the repeat element sequences. A prediction of this model is that there would be a reverse promoter driving either one or both of the Alu element copies. If they are strong and local, they would match one sequence perfectly and match the other well

enough to more frequently bring the two exons together. An alternative hypothesis is that the RNA polymerase reading the AluSx dislodges and starts reading AluJr since the sequences are similar. Then the splicing proceeds as before to fuse *MSMB* exon 2 to *NCOA4* exon 2. In this case there will be a continuous mRNA with a transition somewhere inside the Alu sequences. Alternatively, stabilization of lariat structures required by cis-splicing can be enhanced through the presence of these Alu sequences in the primary transcript

TBP, CAAT and TATA had high match scores. We have already published the observation that the GWAS-associated variant rs10993994 is located in the core $-236/-27$ *MSMB* promoter region and affects CREB binding (18); however, the impact of the risk haplotype on other transcription factors identified here not yet been assayed in vitro.

Androgen-induced gene regulation typically occurs through AR interaction with specific DNA sequences

known as androgen response elements (AREs). Regulation through positive and negative AREs (pARE and nARE) has been reported for AR-target genes, including prostate-specific antigen (PSA) and transforming growth factor β (TGF β) (Fabre et al. 1994; Qi et al. 2012). Sequence analysis revealed two putative ARE-like elements located upstream of *MSMB* and two ARE-like elements in between the *MSMB* and *NCOA4* genes. These elements are designated ARE1 to ARE4 in Fig. 7a. The sequences for *MSMB*

and NCOA4 AREs are very similar to either consensus AREs or some natural ARE motifs, as shown in Figure S2. ARE2 localized to the core MSMB promoter region containing the sequence CACTCAATGTGTTCT; this is similar to the ARE structure found at the proximal promoter region of TGF β (Qi et al. 2012).

MatInspector was also used to identify putative functional frameworks in the regulatory regions of the *MSMB* promoter. We searched for common modules containing two transcription factor-binding sites at a distance between 5 and 50 bp. The modules EBOX–CREB, GATA–SP1, BRNF–RXRF, IRFF–CREB, CAAT–CAAT, OCT1–PBXC, STAT–ETS were identified within the 752 bp *MSMB* promoter sequence (Fig. 7b).

To investigate the regulatory and functional connection of *MSMB* with *NCOA4*, we performed a literature search combined with TF binding site analysis using Genomatix BiblioSphere and MatInspector. Transcripts which showed co-citations with transcription factors, functional co-citations, and co-citations with other genes were selected. Based on these criteria, twenty-one TFs which showed functional co-citations at GFG (gene-for-gene) level 3 were identified. Notably, the *MSMB* gene is functionally connected with the *NCOA4* gene in relation to the androgen receptor signaling pathway and the beta-catenin signaling pathway (Figure S3).

Discussion

Large numbers of genetic loci have been identified through GWAS studies of cancer (Chung and Chanock 2011), but relatively few have begun to be understood at a molecular level. In addition, the effect of associated variants on both transcriptional regulation as well as alternative splicing has been proposed but rarely demonstrated. While alternative splicing is known to be a major source of protein diversity in mammalian cells, a role for transcripts joining exons from two genes (transcription-induced cis- or trans-splicing) is also becoming increasingly clear (Akiva et al. 2006; Gray et al. 1999; Kaye 2009; Parra et al. 2006). For adjacent genes, read-through transcription has been demonstrated in a few cases, but trans-splicing has also been documented. Remarkably, a comprehensive analysis of the 5' transcription start site of 399 annotated protein coding genes (ENCODE pilot project) using pooled 5' RACE products to hybridize with a high-density genome tiling array showed that approximately 50 % of the genes had distal 5' exons that often spanned adjacent genes at distances up to 200 kb (Denoeud et al. 2007). Fusion transcripts are often pathognomonic in hematopoietic malignancies and Ewing's sarcoma. The recent discovery of recurrent gene fusions in prostate (Tomlins et al. 2005)

and lung cancer (Choi et al. 2008; Koivunen et al. 2008; Perner et al. 2008; Rikova et al. 2007) points to their role in common epithelial tumors as well.

In this paper, we document a chimeric transcript, present in both normal and tumor cells, with relevance to prostate cancer. A SNP upstream of *MSMB* (rs10993994) has been implicated by multiple groups in prostate cancer risk by GWAS (Eeles et al. 2008; Pomerantz et al. 2010; Thomas et al. 2008) and we previously reported that *MSMB* transcription was significantly up-regulated in normal prostate tissue compared to prostate tumor tissue and cell lines derived from metastatic prostate cancers (Lou et al. 2009). These observations suggest that *MSMB*, which encodes MSP, and its neighboring gene *NCOA4*, an androgen receptor co-activator, may play an important role in multistep carcinogenesis. Here, we report the existence of common novel fusion transcripts resulting from these two genes. We identified four *MSMB-NCOA4* fusion transcripts in human prostate and trachea tissues by RT-PCR and 5' RACE, all of which incorporated canonical RNA splice sites from both genes. The most abundant chimeric spliced transcript, occurring in 80 % of the events, removes several exons of the upstream gene and the first exon of the downstream gene (Akiva et al. 2006). The four *MSMB-NCOA4* fusion transcripts described in this study fall within this category of common chimeric transcripts.

MSMB and *NCOA4* genes map to human chromosome 10q11, and are situated about 3 kb apart. The predominant fusion transcript, *MSMB-NCOA4* 1 (E2-E2), contains the ATG initiation codon of *MSMB* fused in-frame to *NCOA4* exons 2–10. *NCOA4* is a chromosomal fusion partner of the RET proto-oncogene, a transmembrane receptor of the tyrosine kinase family, that is frequently activated in papillary thyroid carcinoma (Santoro et al. 1994). *NCOA4* interacts with the AR to enhance AR transcriptional activity, through hydrophobic side chain interactions, and *NCOA4* may function as a linker protein between the nuclear receptors and the basal transcription machinery, thereby recruiting or stabilizing the pre-initiation complexes on the promoter (Alen et al. 1999).

Analysis of the splice sites participating in the major fusion transcript revealed that they are canonical splice sites, and in fact, the acceptor in front of *NCOA4* exon 2 is extremely strong. This fusion resembles the 80 % of such fusions that join to the second exon of the downstream gene (Akiva et al. 2006) and the two genes are separated by only 3 KB. This favors the model of cis-read-through for adjacent genes (Akiva et al. 2006). However, there is an AluSX element just 3' of the *MSMB* exon 2, and an AluJr element 5' to *NCOA4* exon 2. It is possible therefore that these elements facilitate a trans-splicing event between hnRNAs of the two genes (Fig. 8). The mechanism proposed by which *Alu* elements mediate alternative splicing

is independent of cis- trans-distinctions; however, it may be required for trans-splicing. It is also interesting that the expression of the fusion transcript is correlated with the expression of *MSMB* and with the genotype 5' to the locus. Allele-specific expression of trans-splicing products has been observed, and therefore additional genetic variants might participate in such epigenetic events. For example, another variant strongly associated with prostate cancer is rs10486567, located in intron 2 of the *JAZF1* gene, another gene known to participate in trans-splicing (Li et al. 2008; Thomas et al. 2008).

Alignment of the predicted human and mouse *MSMB* promoter regions demonstrates a high degree of similarity and conservation. This suggests that transcription of *MSMB* may be regulated by similar mechanisms across mammalian species. The minimal *MSMB* core promoter region was identified as a -236/-27 fragment relative to the previously reported transcription start site. In addition, two negative regulatory elements in the distal and proximal regions of the *MSMB* promoter were confirmed (Fig. 7b). The 210 bp core promoter had the highest transcription activity in all the prostate cancer cell lines we tested, indicating that this fragment is responsible for basal *MSMB* promoter activity. Deletion of the immediate 5'UTR results in significantly enhanced transcription activity in the PCa cell lines, suggesting that negative cis-acting elements are in this region.

Through in silico analysis, the putative transcription factor binding sites CREB, MYOD, STAT, OCT, PBXC, ETS, SP1, TBP, CAAT and TATA, and modules CAAT-CAAT, OCT1-PBXC, STAT-ETS were identified within the core *MSMB* fragment -236/-27. The 3' deletion assay identified 31 bp (-27 to -58) as necessary for the repressor effect (Fig. 6b). These results suggest that repression of the *MSMB* gene requires recruitment of other transcription factors to the 3' end of the promoter sequence. The further deletion from -27 to -58 abrogated promoter activity, demonstrating that the region surrounding rs10993994, located at -57, is critical for *MSMB* promoter activation. Several putative transcription factor binding sites were identified between -27 and -58, including E4F, EGRF, HIC, GATA and CREB. Mutation at rs10993994 destroys a potential binding site for CREB, leading to a sharp decrease of *MSMB* promoter activity. Therefore, the transcription factor binding sites and modules identified in this study are likely to be key controlling elements in the regulation of the *MSMB* gene. These findings provide a basis for further delineating the precise function of each transcription factor in *MSMB* regulation, and revealing the molecular basis of *MSMB* repression.

The androgen receptor regulates the expression of many genes that are essential for male tissue-specific differentiation. The receptor acts by direct binding to AREs found in

the promoters of regulated genes. These AREs are organized as two 5'-TGTTCT-3' like motifs separated by three base pairs. They may vary in structure and be present at considerable distance upstream from regulated promoters. The presence of multiple AREs in the *MSMB/NCOA4* region indicates that these genes might be subjected to AR regulation through these AREs. These observations suggest a mechanism in which multiple transcription factors bind to the *MSMB* promoter and interact with AR through AREs contributing to *MSMB* expression. In addition, the gene product of *NCOA4*, is an AR co-activator that may specifically regulate its own expression and/or the expression of *MSMB*. Further characterization of the predicted AREs in the *MSMB/NCOA4* genes may provide a greater understanding of AR-mediated PCa progression.

In conclusion, this study confirms the presence of a novel fusion transcript between *MSMB* and *NCOA4* expressed in PCa cells and surrounding tissues, giving further insight into the role of this complex locus in PCa susceptibility. The data provide an understanding of the *MSMB* 5' regulatory response elements controlling *MSMB* expression that also probably control the expression of the fusion transcript, and a mechanism through which the fusion transcript may arise. The identification of the *MSMB-NCOA4* fusion transcript and the functional connections between *MSMB*, *NCOA4*, and androgen receptor suggests new markers and new therapeutic targets for PCa.

Materials and methods

Cell lines

The benign immortalized prostate cell line RWPE1 and the PCa cell lines PC3, DU145, LNCaP, PCa2b, NCIH660, PZHPV7, CAHPV10, VCaP, 22RV1, WPMY-1, WPE-Stem and breast cancer cell line SKBR3 and stomach cell line AGS were obtained from American Type Culture Collection (ATCC). Breast cancer cell line MCF10F was purchased from the University of Michigan, SUM229, SUM159, and SUM149 were purchased from Asterand, Inc. Cells were maintained according to the supplier's instructions.

RNA isolation and cDNA synthesis and RT-PCR

Total RNAs were extracted and purified as described (18). One microgram of total RNA was reverse transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche) with oligonucleotide (dT)₁₈ primer according to the manufacturer's instructions. The primers designed for RT-PCR and 5' RACE assays corresponding to regions across the *MSMB* and *NCOA4* genes are listed in Table S1.

RT-PCR was carried out in a volume of 50 μ l containing 100 ng of cDNA and 20 pmol of each primer using Platinum[®] TaqGold HIF Kit (Invitrogen). Thermal cycling conditions included 10 cycles of 94 °C for 30 s, 58 °C for 45 s and 68 °C for 45 s, and 28 cycles of 94 °C for 30 s, 56 °C for 45 s and 68 °C for 45 s. After RT-PCR, products were separated on a 1.5 % agarose gel.

5' RACE assays

5' RACE assays were carried out with both First Choice RLM RACE kit (Ambion) and 5'/3' RACE kit, 2nd Generation (Roche) to confirm the transcription starting site (TSS) of the *MSMB-NCOA4* fusion transcripts, according to the manufacturer's directions.

For sequence analysis, the RT-PCR and 5' RACE products were subcloned into a pCR2.1 vector using a TOPO TA Cloning kit (Invitrogen) according to the manufacturer's instructions. At least twelve clones were sequenced in an ABI 3730 DNA Sequencer (Applied Biosystems) for each product tested. Each experiment was done at least two times.

Construction of expression vectors and transfection

The expression constructs of the full-length *MSMB-NCOA4* transcript were generated by subcloning the corresponding cDNA fragment into pcDNA 3.1⁺ (Invitrogen) and pEGFPC1 (Clontech) vectors. The *MSMB-NCOA4* cDNAs were obtained by RT-PCR with the RT-MSMB-NCOA4 F1 forward primer and the reverse RT-MSMB-NCOA4 Rev1 primer (Table S1). The *MSMB-NCOA4* expression construct contained full-length *MSMB-NCOA4* fusion cDNA, including 141 bp of *MSMB* and 1,886 bp of *NCOA4*, starting at the transcription start site of *MSMB* part of the fusion. The constructs were verified by sequencing.

We have compared three different transfection reagents, FuGENE 6, FuGENE HD and HilyMax. High transfection efficiency was detected in all cell lines when using HilyMax; therefore, we selected HilyMax for transfection experiments in this study. The pcDNA 3.1⁺-MSMB-NCOA4 and pEGFPC1-MSMB-NCOA4 plasmid DNAs were transfected into PC3, DU145 and LNCaP cells using the HilyMax transfection reagent (Dojindo) according to the manufacturer's instructions. Briefly, 24 h before transfection, 1×10^5 to 1×10^6 cells were plated on 100 mm dishes. Equal amounts (3 μ g) of pcDNA 3.1⁺-MSMB-NCOA4 and pcDNA 3.1⁺ alone were individually transfected into each plate. After 24 h of transfection, cells were harvested and total RNA was extracted and purified as described (18). To establish stable cell lines, the PC3 cells transfected with pcDNA 3.1⁺-MSMB-NCOA4 were

selected with 650 μ g/ml G418 in complete RPMI 1640 medium. Transfection efficiency was measured by analysis of the percentage of GFP-positive cells in the PC3 cell line transfected with pEGFPC1-MSMB-NCOA4 plasmid DNA.

The expression level of the *MSMB-NCOA4* fusion transcript in the transfected cells was examined by RT-PCR using RT-MSMB-NCOA4 F1 and RT-MSMB-NCOA4 Rev1 primers (Table S1), and by the TaqMan real-time RT-PCR method. To distinguish between fusion and endogenous transcripts, two primers/probe sets for *MSMB* or *NCOA4* were used. Hs00738230_m1 and Hs00159303_m1 corresponded to *MSMB* exons 1–2 and exons 2–3, respectively, whereas NCOA4 II primer probe sets (Table S1) and Hs00428328_m1 corresponded to *NCOA4* exons 6–7 and exons 1–2, respectively. The expression of the beta-actin gene (Hs99999903_m1) was used to normalize results.

Real-time quantitative RT-PCR

TaqMan[®] Gene expression assay primer and probe (FAM-labeled) sets (Applied Biosystems) and custom-designed TaqMan MGB-labeled primers and probes were used for detection of the mRNA expression levels of *MSMB-NCOA4* fusion, *MSMB (PSP94)*, *NCOA4* and *AR* genes in human tissues and other cancer cell lines (Table S1). Two primer/probe sets were designed to measure fusion transcript levels, with the same forward primer and probe but different reverse primer sequences. The reverse primer of the first *MSMB-NCOA4* set, Assay ME2NE2 I, consisted of 22 nucleotides with 3 bp of the *MSMB* exon 2 sequence at the 3' end of the primer and 19 bp of the *NCOA4* exon 2 sequence. The reverse primer of the second *MSMB-NCOA4* set, Assay ME2NE2 II, was 21 bp in length, containing 10 bp of the *MSMB* exon 2 sequence at the 3' end of the primer (Table S1).

Standard curve construction

Standard curves were generated using a dilution series of plasmids containing full-length cDNA of *MSMB* (GenBank Accession Number BC005257.1) (ATCC), *NCOA4* (GenBank Accession Number NM_005437), *AR* (GenBank Accession Number BC132975), and beta-actin (GenBank Accession Number BC061604) (Open Biosystems). The pcDNA 3.1⁺-MSMB-NCOA4 construct was used for the standard curve to measure levels of fusion transcript in tissues and cancer cell lines. The copy number of plasmid cDNA was calculated by optical density according to the exact molar mass determined from the sequences. Serial dilutions were made to obtain 10^1 – 10^7 copies. The slope and intercept were calculated for each run using linear regression analysis of log copy number versus threshold

cycle (Ct) value for both target genes and beta-actin standard curves. The linear dynamic range and inter-intra assay precision were examined from three separate experiments. The relative mRNA expression level of the target genes was normalized for human tissue and cancer cell lines by the following formula: (copy number of target gene)/(copy number of beta-actin) $\times 10^5$ (Table S2).

Protein expression

In vitro expression construct

The MSMB-NCOA4 fusion protein was expressed using the *in vitro* TNT Quick Coupled Transcription/Translation System (Promega) in the presence of [³⁵S] methionine, according to the manufacturer's protocol (Amersham Pharmacia Biotech).

Expression of proteins in vivo

Whole cell lysates were prepared from the PC3 cell line 72 h after transfection with pcDNA3.1⁺-MSMB-NCOA4. Seventy-five micrograms of whole cell protein were separated in a 4–12 % NuPAGE Bis–Tris gel, transferred to PVDF membrane (Invitrogen). The primary antibodies used were polyclonal goat-anti-PSP94 (R&D system) at a dilution of 1:200, and mouse monoclonal anti-NCOA4 (Abnova) at a dilution of 1:500 to analyze the MSMB-NCOA4 fusion protein. Beta-actin was used as an internal control. HRP-conjugated anti-goat IgG, anti-mouse IgG (1:3,000, Cell Signaling Technology MA, USA) and anti-rabbit IgG were used as secondary antibodies.

To further confirm the identity of the MSMB-NCOA4 fusion protein, the proteins were immunoprecipitated using the Immunoprecipitation Kit—Dynabeads Protein G (Invitrogen) according to the manufacturer's protocol. Five microgram of the polyclonal goat-anti-PSP94 antibody was pre-incubated with 50 μ l of Dynabeads Protein G, and then 200 μ l of cell lysate was added (200–500 μ g protein) to the resuspended Dynabeads–Ab complex, incubated for 30 min, then washed three times with 200 μ l of wash buffer. The immunoprecipitate was electrophoresed and transferred to PVDF membranes as described above. The membranes were blotted with mouse monoclonal anti-NCOA4 antibody against the NCOA4 C-terminal region. We also used the anti-NCOA4 C-terminal antibody to immunoprecipitate protein, and then performed a western blot using the goat-anti-PSP94 antibody.

In silico analysis of the MSMB regulatory region

A 40 kb sequence surrounding the *MSMB* gene was obtained through the Ensembl database and the UCSC

genome browser for human, mouse and chimpanzee. Identification of putative TF-binding sites and modules in the regulatory region upstream of the transcription start site of the *MSMB* gene was performed online at Genomatix using EIDorado, PromoterInspection, MatInspector, BiblioSphere and FrameWorker programs (Genomatix Software, Germany) and at the TFSEARCH website (<http://www.cbrc.jp/research/db/TFSEARCH.html>).

Generation of luciferase reporter plasmids

A promoter fragment was generated by PCR using gene-specific forward primers starting at –716 and reverse primers starting at +36 relative to the transcription start site of the *MSMB* gene from MCF10A (breast epithelial cell) genomic DNA. The PCR product was cloned into the TOPO-TA vector (Invitrogen), and the presence of the C nucleotide polymorphism at both rs10993994 and rs12770171 was confirmed by sequencing. A series of truncated *MSMB* promoter constructs, including 9 deletions from the 5' side and 10 deletions on the 3' side, were created by PCR using the primers shown in Table S3. Luciferase reporter plasmids were generated as described (Lou et al. 2009).

Cell transfection and luciferase assays

Three prostate cancer cell lines, PC3, LNCaP and DU145, were used for the analysis of promoter constructs. Cells were transfected with plasmid DNA and luciferase assay was performed as described (Lou et al. 2009).

Acknowledgments The authors would like to thank Allison Bierly and Wei Tan for critical reading of the manuscript and helpful comments. The project was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, and from SAIC-Fredrick under contract #NO1-CO-12400. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standards The experiments comply with the current laws of the United States of America.

References

- Akiva P, Toporik A, Edelleit S, Peretz Y, Diber A, Shemesh R, Novik A, Sorek R (2006) Transcription-mediated gene fusion in the human genome. *Genome Res* 16:30–36

- Al-Balool HH, Weber D, Liu Y, Wade M, Guleria K, Nam PL, Clayton J, Rowe W, Coxhead J, Irving J, Elliott DJ, Hall AG, Santibanez-Koref M, Jackson MS (2011) Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. *Genome Res* 21:1788–1799
- Alen P, Claessens F, Schoenmakers E, Swinnen JV, Verhoeven G, Rombauts W, Peeters B (1999) Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. *Mol Endocrinol* 13:117–128
- Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT (2007) Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. *Clin Cancer Res* 13:4130–4138
- Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Gronberg H, Xu J (2009) Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. *Hum Mol Genet* 18:1368–1375
- Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. *Cancer Res* 68:4971–4976
- Chung CC, Chanock SJ (2011) Current status of genome-wide association studies in cancer. *Hum Genet* 130:59–78
- Crawford ED (2003) Epidemiology of prostate cancer. *Urology* 62:3–12
- Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F (2010) The rules of DNA recognition by the androgen receptor. *Mol Endocrinol* 24:898–913
- Denoeud F, Kapranov P, Ucla C, Frankish A, Castelo R, Drenkow J, Lagarde J, Alioto T, Manzano C, Chrast J, Dike S, Wyss C, Henrichsen CN, Holroyd N, Dickson MC, Taylor R, Hance Z, Foissac S, Myers RM, Rogers J, Hubbard T, Harrow J, Guigo R, Gingeras TR, Antonarakis SE, Reymond A (2007) Prominent use of distal 5' transcription start sites and discovery of a large number of additional exons in ENCODE regions. *Genome Res* 17:746–759
- Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF (2008) Multiple newly identified loci associated with prostate cancer susceptibility. *Nat Genet* 40:316–321
- Fabre S, Manin M, Pailhoux E, Veyssiere G, Jean C (1994) Identification of a functional androgen response element in the promoter of the gene for the androgen-regulated aldose reductase-like protein specific to the mouse vas deferens. *J Biol Chem* 269:5857–5864
- Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G (1996) Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. *Proc Natl Acad Sci USA* 93:1642–1647
- Gray TA, Saitoh S, Nicholls RD (1999) An imprinted, mammalian bicistronic transcript encodes two independent proteins. *Proc Natl Acad Sci USA* 96:5616–5621
- Horiuchi T, Aigaki T (2006) Alternative trans-splicing: a novel mode of pre-mRNA processing. *Biol Cell* 98:135–140
- Kaye FJ (2009) Mutation-associated fusion cancer genes in solid tumors. *Mol Cancer Ther* 8:1399–1408
- Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 14:4275–4283
- Kumar AR, Li Q, Hudson WA, Chen W, Sam T, Yao Q, Lund EA, Wu B, Kowal BJ, Kersey JH (2009) A role for MEIS1 in MLL-fusion gene leukemia. *Blood* 113:1756–1758
- Li H, Wang J, Mor G, Sklar J (2008) A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. *Science* 321:1357–1361
- Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF Jr, Thomas G, Hunter DJ, Dean M, Chanock SJ (2009) Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. *Proc Natl Acad Sci USA* 106:7933–7938
- Mitelman F, Johansson B, Mertens F (2004) Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. *Nat Genet* 36:331–334
- Mitelman F, Mertens F, Johansson B (2005) Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. *Genes Chromosomes Cancer* 43:350–366
- Nacu S, Yuan W, Kan Z, Bhatt D, Rivers CS, Stinson J, Peters BA, Modrusan Z, Jung K, Seshagiri S, Wu TD (2011) Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. *BMC Med Genomics* 4:11
- Niu Y, Yeh S, Miyamoto H, Li G, Altuwajri S, Yuan J, Han R, Ma T, Kuo HC, Chang C (2008) Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. *Cancer Res* 68:7110–7119
- Parra G, Reymond A, Dabbouseh N, Dermitzakis ET, Castelo R, Thomson TM, Antonarakis SE, Guigo R (2006) Tandem chimerism as a means to increase protein complexity in the human genome. *Genome Res* 16:37–44
- Peng Y, Li CX, Chen F, Wang Z, Ligr M, Melamed J, Wei J, Gerald W, Pagano M, Garabedian MJ, Lee P (2008) Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. *Am J Pathol* 172:225–235
- Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA (2008) EML4-ALK fusion lung cancer: a rare acquired event. *Neoplasia* 10:298–302
- Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Taberero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML (2010) Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. *PLoS Genet* 6:e1001204

- Qi W, Gao S, Chu J, Zhou L, Wang Z (2012) Negative androgen-response elements mediate androgen-dependent transcriptional inhibition of TGF-beta1 and CDK2 promoters in the prostate gland. *J Androl* 33:27–36
- Rabbitts TH (1994) Chromosomal translocations in human cancer. *Nature* 372:143–149
- Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM (2006) Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. *Clin Cancer Res* 12:6018–6022
- Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA (2009) SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. *Cancer Res* 69:2734–2738
- Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 131:1190–1203
- Rogan PK, Faux BM, Schneider TD (1998) Information analysis of human splice site mutations. *Hum Mutat* 12:153–171
- Rowley JD (2001) Chromosome translocations: dangerous liaisons revisited. *Nat Rev Cancer* 1:245–250
- Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A (1994) Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. *Oncogene* 9:509–516
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 448:561–566
- Thierry MD, Thierry MJ (2006) AceView: a comprehensive cDNA-supported gene and transcripts annotation. *Genome Biol* 7:S12–S14
- Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ (2008) Multiple loci identified in a genome-wide association study of prostate cancer. *Nat Genet* 40:310–315
- Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 310:644–648
- Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature* 448:595–599
- Valtonen-Andre C, Savblom C, Fernlund P, Lilja H, Giwercman A, Lundwall A (2008) Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males. *J Androl* 29:330–337
- Yeh S, Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. *Proc Natl Acad Sci USA* 93:5517–5521